

A Comprehensive Analysis of Herbal Medicine's Possible Use in The Management of Chronic Kidney Disease

Anil Kumar^{1*}, Govind Sharma², D. K. Pradhan³

¹Atharva College of Pharmacy, Dhanora, Durg, Chhattisgarh

²KIPS, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India

³Raigarh College of Pharmacy, Raigarh, Chhattisgarh, India

*Corresponding Author E-mail: anilkumarsahu4996@gmail.com

Abstract:

This is a systematic review on herbal medicine's potential role in managing CKD, a progressive condition that poses much health concern worldwide. It explores medicinal plants, including *Phyllanthus niruri*, *Salvia miltiorrhiza*, and *Withania somnifera*, that exhibit nephroprotective properties, such as antioxidant, anti-inflammatory, and anti-fibrotic properties. These therapies have been designed to target the mechanisms of their action through the modulation and reduction of fibrosis with a resultant increase in kidney function and slowing of the progression of CKD. While such encouraging preclinical and clinical data are available, clinical application challenges include standardisation, herb-drug interaction, and regulatory restrictions. The review strongly focuses on this combination of these natural remedies to benefit synergistically with conventional treatments, reduce cost in treatment delivery, and have sustainable solutions for delivering healthcare. Since this analysis now creates a path toward standard protocols and potential further research, more holistic CKD care is approached.

Keywords: Herbal Medicine, Management, Chronic Kidney Disease, End-Stage Renal Disorder

1. INTRODUCTION

Chronic kidney disease CKD is an important health care problem worldwide affecting millions of populations and placing immense burden on health care. CKD is a disorder that involves a progressive loss in kidney function. CKD progresses to serious complications, including end-stage renal disease (ESRD),

cardiovascular disease, and metabolic imbalances [1]. The conventional treatments dialysis and kidney transplantation are quite effective but highly costly, unavailable, and entail considerable physical and emotional strain to the patients. In addition, drug interventions for CKD commonly offer symptomatic instead of pathophysiological

relief with a potential risk of adverse side effects. In this regard, alternative and complementary therapies, especially herbal medicine, have gained much interest in recent times as potential avenues to enhance the management of CKD.

Herbs represent an age-old form of knowledge for several millennia, holding numerous bioactive compounds with the therapeutic potential to aid in curing human diseases. In this respect, for example, nephroprotective effects have been manifested by *Astragalus membranaceus*, *Rheum officinale*, and *Curcuma longa* through antioxidant activity, anti-inflammatory action, and inhibition of renal fibrosis [2]. Natural medicine has been evidenced to modulate oxidative stress which is a fundamental contributor to CKD progression while regulating cytokines to alleviate inflammatory responses. It is also presumed that herbal treatment enhances renal functionality through detoxification and the reactivation of cellular processes for repair. Although these reports are promising, the inclusion of herbal medicine within CKD therapy protocols requires much more information in terms of the mechanisms of such treatments, as well as effectiveness and safety considerations.

Despite the encouraging promise, there are several challenges in the clinical acceptance of herbal medicine in CKD management. The issues of standardization, quality control, and the risk of herb-drug

interactions call for robust scientific evidence. The variations in herbal preparations and the weak regulatory frameworks only add to the complexity of using these herbs extensively [3]. However, with the help of pharmacognosy and biotechnology, the herbal preparations can be standardized with respect to consistency in potency and safety. It's to review the therapeutic potential, possible mechanisms, and limitations of the use of herbal medicine in patients with CKD. This study aims to create a comprehensive, well-rounded outline of the actual state of using herbal medicine within the management and therapy for CKD; thus, there is a review of the established practices and emerging research.

CKD indeed affects millions, and this morbidity and mortality are tremendous issues. CKD is the pathologic process which leads to time-dependent progressive diminution of function of the organs of the group [4]. Cardiovascular diseases, imbalance of electrolyte, and terminal renal failure are the complicating factors; conventional therapies-including dialysis and pharmacotherapy-are rather effective but their limitation lies with the very large costs and in the context of side effects together with a difficulty of availability in any low-resource setups. These challenges have spurred growing interest in alternative and complementary therapies, including herbal medicine.




Figure 1: Chronic Kidney Disease (CKD) [5].

1.1. Objectives of the study

- To examine the role of herbal medicine in CKD management.
- To analyze the therapeutic mechanisms of key herbs in alleviating CKD symptoms and complications.
- To evaluate the safety profiles and potential risks associated with herbal treatments.
- To identify research gaps and provide recommendations for future studies.

1.2. Importance of the Study

- **Historical Significance:** Traditional systems of medicine like Ayurveda, TCM, and Unani are known to possess a history as long as the ages in the area of herbal medication, thereby building a

strong root for natural therapies in managing varied health conditions such as CKD [6].

- **Growing Acceptance:** With the growing interest in integrative medicine, herbal treatments are increasingly becoming recognized as alternative therapies in addition to conventional treatments for Chronic Kidney Disease (CKD).
- **Potential for CKD Management:** Herbal remedies may benefit patients with CKD by maintaining the function of the kidneys, reducing inflammation, and promoting general well-being, which is a crucial need considering the increasing prevalence of the disease.
- **Efficacy and Mechanisms:** It will be possible to assess the efficacy of herbs in the treatment of CKD only when their action is understood at

the biochemical and physiological level, ensuring safe, informed use in clinical practice [7].

- **Sustainable Healthcare:** It's through herbal remedy that inexpensive treatment of costly medicines is offered hence making healthcare even more accessible for resource-limited settings.

2. EVIDENCE-BASED INSIGHTS INTO NEPHROPROTECTIVE HERBS

The most promising herbal remedies with nephroprotective properties are *Phyllanthus niruri*, *Salvia miltiorrhiza*, and *Withania somnifera*, particularly in the scenario of Chronic Kidney Disease (CKD). In preclinical research, *Phyllanthus niruri* possesses the ability to induce a reduction in proteinuria, promote the protection of histology in kidneys, and keep the damage away from the kidneys [8]. *Salvia miltiorrhiza*, often referred to as Danshen, modulates the signaling of oxidative stress and fibrosis and inhibits the process of renal fibrosis, improves GFR, and enhances the function of the kidney. *Withania somnifera*, otherwise called Ashwagandha, is an adaptogen that reverses oxidative stress, maintains renal stability, and reduces inflammation in early-stage CKD. Collectively, the herbs will cover the aspects that control CKD as related to such very crucial factors such as oxidative damage, inflammation, and fibrosis. It will then offer an alternative for natural remedies aside from conventional treatments of the kidneys.

2.1. *Phyllanthus niruri*

Chanca Piedra, scientifically known as *Phyllanthus niruri*, is a potential natural remedy in managing renal disorders such as Chronic Kidney Disease. Its anti-inflammatory and antioxidant properties prevent oxidative stress and inflammation, both of which play a key role in the development of kidney damage [9].

By reducing those factors, kidney injury caused by *Phyllanthus niruri* will be minimised and functional status of kidney is preserved on a long-time scale. Amongst the many tests conducted by researches over animals, scientists noticed that *Phyllanthus niruri* diminishes proteinuria- a central sign of disease or dysfunction found in kidneys while leaking proteins into urination. So, it is estimated that *Phyllanthus niruri* can work on the renormation from leaking proteins during its filtration from kidney.

Apart from this, *Phyllanthus niruri* maintained the histology of the kidneys, the microscopic constitution of the kidney tissues that is damaged in CKD [10]. Preclinical studies have established the fact that animals treated with *Phyllanthus niruri* retained kidney tissue architecture implying the potential of the drug in protection against structure damage resulting from inflammation, oxidative stress, and other pathological processes.

2.2. *Salvia miltiorrhiza*

Salvia miltiorrhiza, otherwise known as Danshen, has been shown to enhance renal function in various diseases, including those of the renal origin in chronic kidney disease (CKD). The most active therapeutic

components exert their effect in the pathways of modulation of oxidative stress and fibrosis. CKD progresses considerably due to increased oxidative stress in the kidneys by free radicals to antioxidants. The active constituents in *Salvia miltiorrhiza* are tanshinones, which are antioxidants, thus scavenging free radicals and protecting kidney tissues from oxidative damage [11].

It also mediates the pathways of fibrosis which are also of paramount importance in the genesis of CKD. *Salvia miltiorrhiza* modulates the signalling pathways participating in the process of fibrosis with the possible slowing and reversing of the fibrotic process. This takes away fibrosis and maintains the structural integrity of the kidneys, preventing further impairment of renal function, thus making it a promising therapeutic agent for the management of CKD.

Clinical trials also prove the efficacy of *Salvia miltiorrhiza* for the improvement of renal function, where GFR shows positive results. It has been established that *Salvia miltiorrhiza* could be a useful adjunct to retard the progression of kidney disease and enhance total renal function of patients with CKD.

2.3. *Withania somnifera*

Withania somnifera, or Ashwagandha, is an herb in the traditional usage of Ayurvedic medicines; it's known for its adaptogenic

action, which helps the body fight stress and maintain a state of balance in various physiological conditions. This, especially on the body part concerning the kidneys, is very useful, particularly in chronic kidney disease with oxidative stress, inflammation, and hormonal imbalances that worsen further deterioration of the kidneys [12]. *Withania somnifera* contains several bioactive compounds known as withanolides that act as potential antioxidants to quench free radicals and prevent the damage caused to the cells and tissues of the kidneys. Such makes it extremely effective in the early stages of CKD wherein renal function has not declined drastically and still can be salvaged. The herb was very promising since it kept and enhanced most markers, especially GFR, and serum creatinine levels thereby delaying the advent of dialysis and other interventions.

In addition, *Withania somnifera* possesses anti-inflammatory activities that may further diminish the inflammatory response in the kidneys and, consequently, further reduce the damage to the renal tissues. The antioxidant, anti-inflammatory, and adaptogenic effects can combine to be of more complete use for *Withania somnifera* to support kidney function more completely and thus make it a good candidate for the treatment of CKD, especially in its early stages.

Table 1: Nephroprotective Effects of Herbal Remedies in Chronic Kidney Disease (CKD) [13].

Herb	Key Compounds / Properties	Mechanisms of Action	Benefits for CKD
Phyllanthus niruri	Anti-inflammatory, Antioxidant	<ul style="list-style-type: none"> - Reduces proteinuria - Preserves renal histology - Mitigates oxidative stress and inflammation 	<ul style="list-style-type: none"> - Protects kidney function - Maintains proper renal filtration - Prevents structural kidney damage
Salvia miltiorrhiza	Tanshinones, Antioxidant, Anti-fibrotic	<ul style="list-style-type: none"> - Neutralizes free radicals - Modulates oxidative stress - Slows fibrosis progression 	<ul style="list-style-type: none"> - Reduces renal fibrosis - Improves glomerular filtration rate (GFR) - Enhances overall kidney function
Withania somnifera	Withanolides, Adaptogenic, Anti-inflammatory	<ul style="list-style-type: none"> - Reduces oxidative damage - Stabilizes renal function (GFR and serum creatinine) - Modulates inflammatory responses 	<ul style="list-style-type: none"> - Protects against early CKD progression - Delays need for invasive treatments - Comprehensive protection via antioxidant, anti-inflammatory, and adaptogenic effects

3. METHODOLOGIES AND FINDINGS

Research on herbal medicine for CKD has employed various methodologies, such as in vitro studies, animal models, and very limited human clinical trials, revealing promising nephroprotective effects but facing challenges such as small sample sizes and formulation variability. Key findings showed herbs like *Phyllanthus niruri*, which reduces oxidative stress and inflammation, and *Curcuma longa* with anti-inflammatory actions. *Salvia miltiorrhiza* reduces fibrosis [14]. This is further buttressed by evidence with *Withania somnifera* stabilizing renal function early. However, problems such as nephrotoxins from *Aristolochia* to even

inconsistencies of concentration of the active compounds prove a need for increased safety standards to be incorporated while standardization with HPLC techniques to enhance the authenticity of the finished preparations. Integrative approaches that combine herbal remedies with conventional treatments, including ACE inhibitors and ARBs, are promising areas for the improved management of CKD; patient education, transparency, and proper information related to the use of herbal therapies can help to avoid adverse drug interactions and promote well-informed safe use of alternative therapies. Regulating and improving good manufacturing practices should remain crucial issues in ensuring broad acceptance and proper use of herbal medicine in managing CKD.

3.1. Herbal Medicine and CKD Pathophysiology

- **Oxidative Stress and Inflammation**

CKD is a condition mainly affecting the kidneys, which are subject to a high degree of oxidative damage due to their filter function and high flow rate of blood. Accumulation of ROS products could damage kidney cells, encourage fibrosis, and cause renal function deterioration [15]. Reinforced damage in kidney tissues is caused by inflammation, mediated by cytokines such as TNF- α and IL-6, which promote fibrosis, eventually leading to kidney failure.

These include herbs such as *Phyllanthus niruri* and *Curcuma longa*, which are found to possess powerful antioxidant and anti-inflammatory properties, hence their ability to neutralize oxidative stress and reduce inflammation. *Phyllanthus niruri* is found to neutralize reactive oxygen species, thereby preventing oxidative damage to the tissues of the kidney, and slowing down the progression of CKD. The levels of inflammatory cytokines, which are high in CKD and contribute to the chronic inflammatory state, are reduced.

The bioactive compound curcumin in *Curcuma longa* had antioxidant and anti-inflammatory properties by scavenging free radicals, inhibiting the oxidative damage to the kidney cells, and targeting the inflammatory pathways involving inhibition of NF- κ B. Curcumin modifies these pathways to reduce the levels of TNF- α and IL-6, subsequently reducing

inflammation and protecting the kidneys. Both *Phyllanthus niruri* and *Curcuma longa* represent promising natural adjuncts in the management of CKD, addressing key pathological processes such as oxidative stress and inflammation [16].

- **Fibrosis Reduction**

The condition known as CKI usually progresses into fibrosis. It is the gradual substitution of normal tissue of the kidneys by excess extracellular matrix (ECM) proteins, for instance, collagen, which brings about thickening and scarring in the kidney tissues, resulting in a poor functional ability that contributes to Chronic Kidney Disease (CKD). Fibrosis plays a central pathological role in CKD progression due to its detrimental effects on filtration ability and impairment of renal function. The major central driver behind fibrosis in the kidney has been identified to be the transforming growth factor-beta (TGF- β) signaling pathway, which promotes the production of ECM proteins while also stimulating fibroblast activation. Dysregulation in TGF- β signaling therefore results in the aberrant accumulation of fibrotic tissue and serves as an essential pathway that would be targeted during therapeutic intervention [17].

Certain herbs, such as *Salvia miltiorrhiza* and *Astragalus membranaceus*, have the potential to halt fibrosis based on their mode of action with TGF- β signaling; this would attenuate kidney injury. *Salvia miltiorrhiza* inhibits TGF- β signaling pathways of fibroblasts transformation to myofibroblast cells, that are responsible for the production of ECM. Traditionally used

medicinal herb *Astragalus membranaceus* attenuates TGF- β -mediate fibrosis by inhibiting the activation of TGF- β and down-stream signaling mediators. This maintaining tissue integrity of the kidneys.

reduction in fibrosis is very beneficial for the prevention of progression of CKD, since it maintains kidney function by m

Table 2: Mechanisms and Benefits of Herbal Remedies in CKD Pathophysiology [18].

Pathophysiological Process	Herbs	Mechanisms	Benefits
Oxidative Stress	<i>Phyllanthus niruri</i> , <i>Curcuma longa</i>	Neutralizes ROS, scavenges free radicals	Slows CKD progression, protects kidneys
Inflammation	<i>Phyllanthus niruri</i> , <i>Curcuma longa</i>	Reduces inflammatory cytokines (TNF- α , IL-6), inhibits NF- κ B	Reduces inflammation, promotes protection
Fibrosis Reduction	<i>Salvia miltiorrhiza</i> , <i>Astragalus membranaceus</i>	Inhibits TGF- β signaling, reduces fibrosis	Prevents scarring, preserves kidney function

3.2.Clinical Studies and Evidence

Chanca Piedra or *Phyllanthus niruri* has been studied widely due to its potential therapeutic applications for kidney-related disorders, particularly proteinuria and oxidative stress. It was observed in animal studies that *Phyllanthus niruri* exhibited significant reductions in proteinuria, suggesting that it has a protective role for the kidneys and maintenance of renal filtration. Strong antioxidant properties of this plant also mitigate oxidative stress, a primary contributing factor in CKD progression [19].

Clinical trials have evaluated *Salvia miltiorrhiza*, Danshen, which improves GFRs for the kidneys-an important measure of kidney function. Thus, this would suggest its usefulness in the treatment of patients having renal dysfunction. Aside from its antioxidant properties, it has been

generally modulated through the pathways of oxidative stress and fibrosis.

Astragalus membranaceus is an herb known well in traditional Chinese medicine. There is now strong evidence showing enhancement of the immune response of CKD patients following treatment with this herb. Better immune responses for CKD patients treated with *Astragalus membranaceus* are, therefore, key elements in controlling infection and inflammation associated with the diseases [20]. *Curcuma longa*, also referred to as turmeric, was studied in respect to its effect on oxidative damage, and preclinical studies suggested curcumin lowered markers of oxidative damage in kidney tissues, indicating a protective effect of curcumin on renal cells from damage due to free radicals.

The drug ashwagandha, scientifically known as *Withania somnifera*, has highly relevant results to treatment in clinical trials

which link it to its maintenance of stability of renal function in early stages of CKD. Early intervention in CKD management will be crucial as this will prevent the degradation of kidneys further. It will be so when the GFR and serum creatinine will be

kept maintaining markers of kidney health. Through *Withania somnifera*, the individual can proactively manage early-stage CKD, thereby delaying more invasive procedures like dialysis.

Table 3: Key Findings and Study Types of Herbal Remedies in CKD Research [21].

Herb Name	Key Findings	Study Type
<i>Phyllanthus niruri</i>	Reduced proteinuria and oxidative stress	Animal Study
<i>Salvia miltiorrhiza</i>	Improved glomerular filtration rates	Clinical Trial
<i>Astragalus membranaceus</i>	Enhanced immune response in CKD patients	Meta-analysis
<i>Curcuma longa</i>	Lowered markers of oxidative damage	Preclinical
<i>Withania somnifera</i>	Stabilized renal function in early-stage CKD	Clinical Study

3.3. Safety and Standardization

- Safety Concerns**

Aristolochia is a medicinal herb with a potential for nephrotoxicity due to its aristolochic acids, which induce acute kidney injury, chronic kidney disease (CKD), renal failure, and urothelial cancer. The adverse nephrotoxic effects have necessitated the removal of this herbal product from pharmacopoeias and health guidelines. Thus, in order to prevent the adverse effect on kidney function, it is important to track the purity of the herbal preparations and proper dosing of these products containing *Aristolochia* [22]. Because herbal products are not under tight regulations and quality control, there is a greater chance of contamination with harmful compounds or inappropriate

dosing. Thus, standardization of proper active ingredient concentration with the elimination of harmful compounds requires accurate measurement and correct dosing. However, by using well-established and credible manufacturers for herbal products and sticking to recommended dosages, one can reduce such risks. Advise people on herbal remedies for kidneys to seek the guidance of health care providers for advice where the person has other kidney issues or is on some medication. In that case, the patients could enjoy the potential of herbs to help their renal function without hampering it further.

- Standardization Challenges**

Challenges persist when herbal remedies, especially for chronic kidney diseases, are involved since the formulations often vary widely in their concentrations of active compounds. Such disparities are attributed

to aspects such as species variation among the plants used, growth conditions, time of harvest, and method of processing. This makes it hard to ensure the efficacy and safety of herbal remedies because patients might receive either too much or too little of the active ingredients, leading to ineffective treatment or adverse effects [23].

Such a lack of standardization makes clinical trials and research studies on herbal medicine more complicated because the results cannot easily be reproducible or comparable between studies, thanks to the variance in the quality of herbal products applied in different studies. Such an inconsistency has been a factor limiting the determination of the absolute effectiveness of some herbal remedies, thereby limiting their general acceptance in mainstream medicine.

This problem can be overcome through attempts in the regulatory framework and control measure of quality for herbal products. There could be regulation on identification, preparation, and dosage for herbal medicine to ensure the correct content of active ingredients with no adulteration or contamination. The manufacture of herbal medicine shall observe GMP for maintaining consistent quality with minimum variation [24].

This makes it possible with advanced technologies such as HPLC and MS to identify exactly what is present in herbal formulation, which ensures consistency. In that respect, standardization of herbal medicine will prove to be the way forward toward better therapy and acceptance in medical practice, bringing natural treatments to the patient without giving up either safety or effectiveness.

Table 4: Summary of Research Studies on Chronic Kidney Disease (CKD) [25].

Author Name	Topic Covered	Research Study Title
Lv and Zhang (2019) [26]	Global prevalence of CKD, its impact on individuals and healthcare systems	Global Prevalence and Burden of Chronic Kidney Disease: Implications for Healthcare and Public Health
Ma et al. (2020) [27]	Use of deep learning-based artificial neural networks (ANN) for detection and diagnosis of CKD	Deep Learning-Based Artificial Neural Networks for the Detection and Diagnosis of Chronic Kidney Disease
Mafrá et al. (2021) [28]	Role of food as medicine, dietary interventions in CKD management	The Role of Food as Medicine in Targeting the Uraemic Phenotype in Chronic Kidney Disease Patients
Major et al. (2018) [29]	Relationship between CKD and cardiovascular risk factors	The Relationship Between Chronic Kidney Disease and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis

Mantovani et al. (2022) [30]	Connection between non-alcoholic fatty liver disease (NAFLD) and CKD development	Non-Alcoholic Fatty Liver Disease and the Risk of Incident Chronic Kidney Disease: A Meta-Analysis
Nelson et al. (2019) [31]	Development of risk prediction models for incident CKD, based on clinical, demographic, and laboratory data	Development and Validation of Risk Prediction Equations for Incident Chronic Kidney Disease

3.4. Integrative Approaches

- **Combining Herbal Treatments with Conventional Therapies**

It seems promising to combine herbal medicine with conventional therapies like ACE inhibitors and ARBs in the treatment of CKD. These are the only treatments for CKD that could potentially suppress proteinuria, which further slows the disease process through renin-angiotensin-aldosterone system modulations. In many cases, these therapies may also be limited due to side effects or progression of renal damage [32]. Complementary to these therapies, herbal treatments, especially those with nephroprotective properties, can target additional pathways involved in the progression of CKD. Herbal diuretics, such as *Hibiscus sabdariffa* and *Taraxacum officinale*, can reduce fluid retention in CKD patients without the potassium imbalances associated with pharmacological diuretics. However, close monitoring is required to avoid potential

herb-drug interactions that may undermine treatment efficacy or patient safety.

- **Patient Education for Safe and Informed Use**

Integrate educating patients on the safe use of herbal remedies along with prescribed drugs in chronic kidney disease. In many places, especially where the use of herbal medicine is quite prevalent, the patient may already be using herbal treatments without letting the healthcare providers know. Such interactions are often unintended, reducing the efficacy of the conventional drugs, or cause adverse effects. Discussions about herbal use should be undertaken by healthcare providers, emphasizing openness [33]. Patient education programs should give information regarding the benefits and risks of combined herbal and conventional therapy as well as educate on recognition of adverse effects. Education in proper sourcing of good quality herbal products from reliable manufacturers with minimal contamination risks is necessary to enhance management of CKD and quality of life.

Table 5: Integrative Approaches in CKD Management: Herbal and Conventional Therapies [34].

Approach	Herbal Treatments	Conventional Therapies	Benefits	Considerations
----------	-------------------	------------------------	----------	----------------

Combination of Herbal and Conventional Therapies	Hibiscus sabdariffa, Taraxacum officinale (diuretics)	ACE inhibitors, ARBs	Reduces proteinuria, slows disease progression, alleviates fluid retention	Monitor for herb-drug interactions and side effects
Patient Education	Safe use of herbal remedies alongside prescribed medications	N/A	Informed decision-making, safe herbal use, prevention of adverse effects	Focus on sourcing quality herbs and ensuring transparency in use

4. DISCUSSION

4.1. Interpretation and Analysis

Herbal medicine presents an enormous promise in the treatment of chronic kidney disease, targeting critical pathological mechanisms like oxidative stress, inflammation, and fibrosis that define the progression of disease. Various herbs, such as *Salvia miltiorrhiza* and *Phyllanthus niruri*, have shown their nephroprotective effects both in preclinical and clinical studies due to their antioxidant and anti-inflammatory properties. Moreover, *Rheum officinale*, among others, has shown great potential in blocking the development of renal fibrosis through interference with profibrotic signalling pathways [35]. Although the studies have some encouraging results, heterogeneity in methods among different studies, such as variation in sample size, dosing regimen, and study period, has been a significant obstacle to the generalization of results and the standardization of treatment regimens. It is further complicated by the fact that few large-scale, well-designed clinical trials have been carried out to prove the safety and efficacy of such treatments in a wide range of patients. However, by combining

herbal medicine with conventional therapies such as ACE inhibitors and ARBs, the therapy could potentially target several parts of the pathology of CKD in a synergistic way. This integrative approach may not only enhance therapeutic outcomes but also present a cost-effective and holistic approach for the management of CKD, especially within resource-poor environments.

4.2. Implications and Significance

The inclusion of herbal medicine in treatment plans for patients with CKD has far beyond financial cost-saving implications, focusing on the effort to minimize direct and indirect economical burdens related with CKD care, particularly low resource settings wherein expensive conventional remedies like dialysis and renal transplants cannot at times be as readily available. It will be more reasonably priced and may be culturally appropriate in many traditions, making the solution appear more realistically as an additive or alternative form of therapy. Moreover, such holistic herbal practice often treats underlying inflammation, oxidative stress, as well as potential fibrosis to treat the

primary cause of any disease [36]. This may appeal well to the patients who want a more comprehensive care approach. It may help in improving patient compliance by reducing the use of polypharmacy and providing a more integrative treatment experience. Moreover, incorporating herbal remedies in the management protocol of CKD may improve outcomes by synergistically targeting multiple pathways of the disease, especially in combination with conventional treatments such as ACE inhibitors and ARBs. This strategy is likely to increase the accessibility and efficacy of therapies, thereby enhancing the quality of life for CKD patients and reducing the economic burden on health care systems.

4.3. Gaps and Future Research Directions

- **Conduct Standardized, Large-Scale Clinical Trials to Validate Preclinical Findings:** Whereas many promising nephroprotective effects have been documented through preclinical studies on different herbal remedies, findings remain largely unvalidated in human populations [37]. It is thus high time that large multicenter clinical trials, standardized with a methodology of conducting the safety and efficacy profile with therapeutic potential in patients with CKD, were to be designed and conducted. Such trials should involve diverse patient demographics, comprehensive endpoints, such as progression to end-stage renal disease, and changes in biomarkers, and long-term follow-ups to provide robust evidence for their clinical application.
- **Investigate the Pharmacokinetics and Pharmacodynamics of Key Herbal Compounds:** Understanding the ADME of active constituents in herbal medicinal products is one of the more important factors determining the optimization of their therapeutic applications [38]. The needed research should find bioactive ingredients, their pharmacological interactions with conventional CKD drugs, and their dose-responses. All these would unveil mechanisms of actions, reduce toxicity, and advance the accuracy in dosing herbs in CKD management.
- **Develop Guidelines for the Safe and Effective Use of Herbal Medicine in CKD:** Lack of standardized protocols for the administration of herbal medicine in the treatment of CKD presents a major challenge to its more widespread adoption in clinical practice. Future research should work towards the development of evidence-based guidelines stipulating dosing, duration of therapy, and contraindications [39]. It must also consider herb-drug interaction, quality control measures of herbal products, and safe use of herbal remedies in concert with other conventional therapies.

- **Explore the Role of Herbal Medicine in Preventing CKD Progression in At-Risk Populations:** Apart from being a useful adjuvant treatment in managing CKD, herbal medicine might play a prophylactic role in populations predisposed to CKD, for instance, diabetes and hypertension, and a history of kidney diseases [40]. It should, therefore be determined if such interventions could help stop or even delay the disease process at its initial stages in early-stage CKD or even in pre-CKD conditions. Preventive studies could focus on herbs with demonstrated anti-inflammatory, antihypertensive, and renal-protective properties, offering new strategies for reducing the global burden of CKD.

5. CONCLUSION

Herbal medicine, therefore, is a potential remedy for the treatment of chronic kidney disease, targeting primary pathological mechanisms including oxidative stress, inflammation, and fibrosis in the progression of the disease. Some of the most active herbs include *Phyllanthus niruri*, *Salvia miltiorrhiza*, *Withania somnifera*, and *Astragalus membranaceus*, among others, showing nephroprotective effects with reduced proteinuria, improved glomerular filtration rate, and decreased renal fibrosis. Although promising evidence is reported both in the preclinical and clinical stages, challenges such as standardization, variability of active compounds, and herb-drug interaction risks

impede wider clinical application. Integrating herbal therapies with conventional treatments such as ACE inhibitors and ARBs can be beneficial, offering synergistic benefits and cost-effective, sustainable health care solutions in resource-limited settings. This review bridges traditional practice and modern nephrology with a call for evidence-based validation through standardized protocols, comprehensive clinical trials robust regulatory frameworks, and advanced technologies such as high-performance liquid chromatography (HPLC) to ensure consistent potency and safety. In addition to this, there is patient education and provider strategy in preventative care that also extends the possible role of herbal medicine in complete management of CKD so as to avail integrative kidney care solutions within personalized science base.

5.1. Summary of Main Insights and Conclusions

- Herbal medicine holds great promise in the management of chronic kidney disease (CKD) by addressing some of the major pathological mechanisms like oxidative stress, inflammation, and fibrosis that are involved in the progression of the disease.
- Some of the well-known herbs like *Phyllanthus niruri*, *Salvia miltiorrhiza*, *Withania somnifera*, and *Astragalus membranaceus* have shown nephroprotective effects through different mechanisms, such as decreasing proteinuria, enhancing GFR, and preventing renal fibrosis.

- Despite preclinical and clinical evidence that convincingly supports these herbal remedies as effective, broader clinical acceptance has been limited due to issues with standardization and variability in the active compounds within the herbs as well as risk of herb-drug interactions.
- Incorporating herbal therapies together with conventional drugs such as ACE inhibitors and ARBs has yielded promising synergies, enhanced efficacy of treatment, and slowed down the progression of CKD.

5.2. Reiteration of the Importance of the Review

- This review bridges the gap between traditional medicinal practices and modern nephrology, showing how herbal remedies hold promise as an inexpensive and sustainable form of CKD management.
- This study thus synthesizes the existing evidence and points out the need for including alternative therapies in the holistic care models, more so for resource scarce areas where conventional therapy is limited.
- The review sets out the context of increasing interest in integrative medicine, requiring evidence-based efforts to validate and optimize the usage of herbal remedy.

5.3. Recommendations

- **Standardization and Quality Control:** Standardize the

cultivation, processing, and formulation of herbal medicines to ensure uniform potency and safety.

- **Comprehensive Clinical Trials:** Carry out large, multicenter clinical trials with standardized methods to establish the efficacy and safety of herbal medicines in various populations.
- **Regulatory Frameworks:** Develop rigorous regulatory frameworks to help integrate herbal medicine into standard CKD treatment regimens.
- **Education and Awareness:** Educate patients and healthcare providers on the safe and informed use of herbal medicine, focusing on the need for high-quality products and monitoring for herb-drug interactions.
- **Integrative Approaches:** Integrate traditional and conventional medicine practitioners to develop treatment programs tailored for individuals whose unique scenarios surround the complexity of CKD.
- **Focus on Preventative Care:** Discuss the role of herbal remedies in patients at risk of progressing to CKD from already established conditions, such as diabetes or hypertension, to help alleviate the worldwide burden of CKD.
- **Leveraging Advanced Technology:** Incorporate techniques such as HPLC and mass spectrometry to accurately identify

and quantify the active principles of herbal drugs.

REFERENCES

1. Adapa, S., Chenna, A., Balla, M., Merugu, G. P., Koduri, N. M., Daggubati, S. R., ... & Konala, V. M. (2020). COVID-19 pandemic causing acute kidney injury and impact on patients with chronic kidney disease and renal transplantation. *Journal of clinical medicine research*, 12(6), 352.
2. Agarwal, R., Sinha, A. D., Cramer, A. E., Balmes-Fenwick, M., Dickinson, J. H., Ouyang, F., & Tu, W. (2021). Chlorthalidone for hypertension in advanced chronic kidney disease. *New England Journal of Medicine*, 385(27), 2507-2519.
3. Ali, B. H., Al-Salam, S., Al Suleimani, Y., Al Kalbani, J., Al Bahlani, S., Ashique, M., ... & Schupp, N. (2018). Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. *Basic & Clinical Pharmacology & Toxicology*, 122(1), 65-73.
4. Almansour, N. A., Syed, H. F., Khayat, N. R., Altheeb, R. K., Juri, R. E., Alhiyafi, J., ... & Olatunji, S. O. (2019). Neural network and support vector machine for the prediction of chronic kidney disease: A comparative study. *Computers in biology and medicine*, 109, 101-111.
5. Badve, S. V., Pascoe, E. M., Tikku, A., Boudville, N., Brown, F. G., Cass, A., ... & Johnson, D. W. (2020). Effects of allopurinol on the progression of chronic kidney disease. *New England Journal of Medicine*, 382(26), 2504-2513.
6. Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020). Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment. *Journal of the American Society of Nephrology*, 31(3), 456-468.
7. Byrne, C. D., & Targher, G. (2020). NAFLD as a driver of chronic kidney disease. *Journal of hepatology*, 72(4), 785-801.
8. Carrero, J. J., González-Ortiz, A., Avesani, C. M., Bakker, S. J., Bellizzi, V., Chauveau, P., ... & Fouque, D. (2020). Plant-based diets to manage the risks and complications of chronic kidney disease. *Nature Reviews Nephrology*, 16(9), 525-542.
9. Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic kidney disease diagnosis and management: a review. *Jama*, 322(13), 1294-1304.
10. Conroy, A. L., Opoka, R. O., Bangirana, P., Idro, R., Ssenkusu, J. M., Datta, D., ... & John, C. C. (2019). Acute kidney injury is associated with impaired cognition and chronic kidney disease in a prospective cohort of children with severe malaria. *BMC medicine*, 17, 1-12.
11. de Boer, I. H., Caramori, M. L., Chan, J. C., Heerspink, H. J., Hurst, C., Khunti, K., ... & Rossing, P. (2020). KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney international*, 98(4), S1-S115.

12. Ekrikpo, U. E., Kengne, A. P., Bello, A. K., Effa, E. E., Noubiap, J. J., Salako, B. L., ... & Okpechi, I. G. (2018). Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. *PloS one*, 13(4), e0195443.
13. ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., ... & Gabbay, R. A. (2023). 11. Chronic kidney disease and risk management: standards of care in diabetes—2023. *Diabetes Care*, 46(Supplement_1), S191-S202.
14. Fang, C. Y., Lou, D. Y., Zhou, L. Q., Wang, J. C., Yang, B., He, Q. J., ... & Weng, Q. J. (2021). Natural products: potential treatments for cisplatin-induced nephrotoxicity. *Acta Pharmacologica Sinica*, 42(12), 1951-1969.
15. Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., ... & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. *Clinical Nutrition*, 40(4), 1644-1668.
16. Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., ... & FIDELIO-DKD Investigators. (2021). Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. *Circulation*, 143(6), 540-552.
17. Gai, Z., Wang, T., Visentin, M., Kullak-Ublick, G. A., Fu, X., & Wang, Z. (2019). Lipid accumulation and chronic kidney disease. *Nutrients*, 11(4), 722.
18. Groopman, E. E., Marasa, M., Cameron-Christie, S., Petrovski, S., Aggarwal, V. S., Milo-Rasouly, H., ... & Gharavi, A. G. (2019). Diagnostic utility of exome sequencing for kidney disease. *New England Journal of Medicine*, 380(2), 142-151.
19. Han, Y., Balkrishnan, R., Hirth, R. A., Hutton, D. W., He, K., Steffick, D. E., & Saran, R. (2020). Assessment of prescription analgesic use in older adults with and without chronic kidney disease and outcomes. *JAMA network open*, 3(9), e2016839-e2016839.
20. Hsu, C. Y., Yang, W., Parikh, R. V., Anderson, A. H., Chen, T. K., Cohen, D. L., ... & Go, A. S. (2021). Race, genetic ancestry, and estimating kidney function in CKD. *New England Journal of Medicine*, 385(19), 1750-1760.
21. Jang, H. R., Kang, D., Sinn, D. H., Gu, S., Cho, S. J., Lee, J. E., ... & Gwak, G. Y. (2018). Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. *Scientific reports*, 8(1), 4718.
22. Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021). Chronic kidney disease. *The lancet*, 398(10302), 786-802.
23. Kuo, C. C., Chang, C. M., Liu, K. T., Lin, W. K., Chiang, H. Y., Chung, C. W., ... & Chen, K. T. (2019). Automation of the kidney function prediction and classification through ultrasound-based kidney imaging using deep learning. *NPJ digital medicine*, 2(1), 29.

24. Liu, P., Quinn, R. R., Lam, N. N., Al-Wahsh, H., Sood, M. M., Tangri, N., ... & Ravani, P. (2021). Progression and regression of chronic kidney disease by age among adults in a population-based cohort in Alberta, Canada. *JAMA network open*, 4(6), e2112828-e2112828.
25. Luo, L., Jiang, J., Wang, C., Fitzgerald, M., Hu, W., Zhou, Y., ... & Chen, S. (2020). Analysis on herbal medicines utilized for treatment of COVID-19. *Acta Pharmaceutica Sinica B*, 10(7), 1192-1204.
26. Lv, J. C., & Zhang, L. X. (2019). Prevalence and disease burden of chronic kidney disease. *Renal fibrosis: mechanisms and therapies*, 3-15.
27. Ma, F., Sun, T., Liu, L., & Jing, H. (2020). Detection and diagnosis of chronic kidney disease using deep learning-based heterogeneous modified artificial neural network. *Future Generation Computer Systems*, 111, 17-26.
28. Mafrá, D., Borges, N. A., Lindholm, B., Shiels, P. G., Evenepoel, P., & Stenvinkel, P. (2021). Food as medicine: targeting the uraemic phenotype in chronic kidney disease. *Nature Reviews Nephrology*, 17(3), 153-171.
29. Major, R. W., Cheng, M. R., Grant, R. A., Shantikumar, S., Xu, G., Oozeerally, I., ... & Gray, L. J. (2018). Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. *PloS one*, 13(3), e0192895.
30. Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J. M., ... & Targher, G. (2022). Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut*, 71(1), 156-162.
31. Nelson, R. G., Grams, M. E., Ballew, S. H., Sang, Y., Azizi, F., Chadban, S. J., ... & Shalev, V. (2019). Development of risk prediction equations for incident chronic kidney disease. *Jama*, 322(21), 2104-2114.
32. Ozturk, S., Turgutalp, K., Arici, M., Odabas, A. R., Altiparmak, M. R., Aydin, Z., ... & Ates, K. (2020). Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. *Nephrology Dialysis Transplantation*, 35(12), 2083-2095.
33. Peltzer, K., & Pengpid, S. (2019). The use of herbal medicines among chronic disease patients in Thailand: a cross-sectional survey. *Journal of multidisciplinary healthcare*, 573-582.
34. Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021). Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. *Frontiers in Medicine*, 8, 642296.
35. Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2019). Inflammation and oxidative stress in chronic kidney disease—potential therapeutic role of minerals, vitamins and plant-derived

- metabolites. International journal of molecular sciences, 21(1), 263.
36. Rhee, C. M., Ahmadi, S. F., Kovesdy, C. P., & Kalantar-Zadeh, K. (2018). Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. *Journal of cachexia, sarcopenia and muscle*, 9(2), 235-245.
 37. Shlipak, M. G., Tummalaipalli, S. L., Boulware, L. E., Grams, M. E., Ix, J. H., Jha, V., ... & Zomer, E. (2021). The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney international*, 99(1), 34-47.
 38. Tuttle, K. R., Alicic, R. Z., Duru, O. K., Jones, C. R., Daratha, K. B., Nicholas, S. B., ... & Norris, K. C. (2019). Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. *JAMA network open*, 2(12), e1918169-e1918169.
 39. Wang, J., Zhang, L., Tang, S. C. W., Kashihara, N., Kim, Y. S., Togtokh, A., ... & Zhao, M. H. (2018). Disease burden and challenges of chronic kidney disease in North and East Asia. *Kidney international*, 94(1), 22-25.
 40. Yang, B., Xie, Y., Guo, M., Rosner, M. H., Yang, H., & Ronco, C. (2018). Nephrotoxicity and Chinese herbal medicine. *Clinical Journal of the American Society of Nephrology*, 13(10), 1605-1611.